A comprehensive view of pfizer inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer pays US$11.6B for Biohaven’s CGRP inhibitor portfolio, as Pfizer looks to grow oral CGRP business to over US$6B in peak sales; deal includes migraine drug Nurtec ODT, five preclinical CGRP candidates, intranasal migraine treatment spray
Published: May 11, 2022 by FiercePharma
COVID-19 vaccine makers prepare for smaller booster vaccine market as demand for first shots falls; global booster shot market, including people over 50, adults with health risk factors or who work in high-risk occupations, estimated at 1.7 billion people
Published: May 10, 2022 by CE Noticias Financieras
Commentary: mRNA technology used by Pfizer, Moderna for COVID vaccines could end up unlocking much more for future of health care; numerous mRNA vaccine candidates are being researched, undergoing clinical trials for treating cancer, HIV, flu, ebola, more
Published: May 09, 2022 by Bay City Times
Pfizer starting Phase 3 study in US of injectable fordadistrogene movaparvovec mini-dystrophin gene therapy for ambulatory patients with Duchenne muscular dystrophy after FDA lifts clinical hold on drug; DMD has very limited treatment options
Published: May 09, 2022 by Contify Life Science News
Pfizer reports Q1 net profit up 61% from a year ago at US$7.9B, with revenue up 77% year-over-year at US$25.7B; growth driven by Comirnaty COVID-19 vaccine sales of US$13.2B, sales of Paxlovid nirmatrelvir and ritonavir COVID-19 treatment of US$1.5B
Published: May 05, 2022 by SeeNews Pharmaceuticals

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count